HUA MEDICINE (SHANGHAI) LTD. Funds and ETFs Hua Medicine (Shanghai) Ltd.
Equities
2552
KYG4644K1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 HKD | -1.86% |
|
+3.27% | -19.80% |
| 28/03 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
ETFs positioned on Hua Medicine (Shanghai) Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.66% | 4 M€ | -27.92% | ||
| 0.00% | 112 M€ | +5.37% | - | |
| 0.00% | 4 M€ | -4.41% | - |
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
27/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.61
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| -19.80% | 202M | |
| +9.60% | 115B | |
| +13.29% | 107B | |
| -13.35% | 22.31B | |
| -3.52% | 21.6B | |
| -5.71% | 18.23B | |
| -38.57% | 17.62B | |
| +7.79% | 14.26B | |
| +34.59% | 12.37B | |
| -26.81% | 8.28B |
- Stock Market
- Equities
- 2552 Stock
- Funds and ETFs Hua Medicine (Shanghai) Ltd.
